நிறுவனம் இசைக்கருவி வகை மாத்திரை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நிறுவனம் இசைக்கருவி வகை மாத்திரை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நிறுவனம் இசைக்கருவி வகை மாத்திரை Today - Breaking & Trending Today

Intec Pharma Announces Filing of 2020 Annual Report on Form 10-K


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Intec Pharma Announces Filing of 2020 Annual Report on Form 10-K
Intec Pharma LtdMarch 17, 2021 GMT
JERUSALEM , March 16, 2021 (GLOBE NEWSWIRE) Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that it has filed its annual report on Form 10-K for the year ended December 31, 2020 with the U.S. Securities and Exchange Commission. A copy of the annual report is available on Intec’s website, www.intecpharma.com, by selecting “Investors” and then “Financials” and “SEC Filings”.
You may request a copy of the Company’s Form 10-K, at no cost to you, by writing to the Chief Financial Officer of the Company at 12 Hartom Street, Har Hotzvim, Jerusalem 9777512, Israel or by calling the Company at +972 (2) 586 4657. ....

Israel General , Wintec Pharma , Har Hotzvim , Exchange Commission , Company Form , Intec Pharma Ltd , Company Accordion Pill , Chief Financial Officer , Accordion Pill , Investor Relations , Proposed Merger , Decoy Biosystems , Registration Statement , Decoy Biosystem , Annual Report , Private Securities Litigation Reform , Pharma Investor Contact , Corporate News , Pharmaceutical Manufacturing , Government Regulations , Ownership Changes , Middle East , Sec Filings , Product Approvals , New Products And Services , Government And Politics ,

Intec Pharma and Decoy Biosystems Announce Merger Agreement


Intec Pharma and Decoy Biosystems Announce Merger Agreement
USA - English
Investigational New Drug Application Filing Expected in 2H 2021
News provided by
Share this article
Share this article
JERUSALEM, March 15, 2021 /PRNewswire/ Intec Pharma Ltd. (NASDAQ: NTEC) ( Intec or the Company ) announced today that it has entered into a definitive agreement for a business combination with Decoy Biosystems, Inc., a privately-held, preclinical-stage biotechnology company developing novel, multi-targeted products that safely prime both innate and adaptive anti-tumor and anti-viral immune responses.
The combined company will advance its immunotherapy platform to battle a variety of tumor types and chronic viral infections. Decoy previously held a pre-IND meeting with the FDA, currently plans to file an IND in the second half of 2021 and to initiate a Phase I clinical trial in 2022 targeting solid tumors and lymphomas. ....

Israel General , San Diego , United States , Wintec Pharma , Roger Pomerantz , Har Hotzvim , Michaelj Newman , Jeffreya Meckler , Prnewswire Intec Pharma Ltd , Intec Pharma Ltd , Company Current Report On Form , Decoy Biosystems Inc , Company Accordion Pill , Decoy Biosystems , Vice Chairman , Chief Executive Officer , Accordion Pill , Jeffrey Meckler , Michael Newman , Chief Scientific Officer , Johnson Innovation , Investor Relations , Proposed Merger , Registration Statement , Decoy Biosystem , Annual Report ,